Approval for a drug meant to treat children with a severe form of spinal muscular atrophy -- which costs over $2 million for a single treatment -- was based on manipulated data provided by the drug's maker, the FDA reports.
Aug. 7, 2019 -- The maker of the world's most expensive drug gave manipulated data to the U.S. Food and Drug Administration when it approved the drug, the agency said Tuesday., a leading genetic cause of infant death. The drug costs $2.125 million for a one-time treatment,A month after the approval, the FDA discovered a"data manipulation issue that impacts the accuracy of certain data from product testing performed in animals," according to the agency.
The FDA said the drug's maker AveXis, a unit of Novartis, knew about the data problem before the drug was approved, but did not inform the FDA until after the drug was given the green light,"The agency will use its full authorities to take action, if appropriate, which may include civil or criminal penalties," according to Peter Marks, an FDA official.
Despite the inaccurate data, the FDA said it"remains confident that Zolgensma should remain on the market." "We maintain that the totality of the evidence demonstrating the product's effectiveness and its safety profile continue to provide compelling evidence supporting an overall favorable benefit-risk profile," Novartis said in an emailed statement,"At no time during the investigation did the findings indicate issues with product safety, efficacy or quality," according to the company.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA raises accuracy questions over trial data of $2 million gene therapy drugMore than 2 months after the FDA approved an expensive new gene therapy drug for a rare disease in children, the agency said it has major questions about the accuracy of some of the testing data.
Baca lebih lajut »
FDA Says Data Manipulated for Novartis Gene Therapy DrugThe Food and Drug Administration said “data manipulation” took place during the clinical trial of Zolgensma, the world’s most expensive drug, but officials said the gene therapy product still should stay on the market.
Baca lebih lajut »
FDA panel backs Gilead's HIV prevention drug Descovy, except in womenAn FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc's ...
Baca lebih lajut »
FDA investigating 127 reports of seizures after vapingThe FDA cautions it's unclear whether e-cigarettes caused the seizures.
Baca lebih lajut »
U.S. FDA says some data testing Novartis' $2 million gene therapy was manipulatedThe U.S. Food and Drug Administration said on Tuesday that some data from early ...
Baca lebih lajut »
FDA says some data testing Novartis' $2 million gene therapy was manipulatedThe U.S. Food and Drug Administration said on Tuesday that some data from early ...
Baca lebih lajut »